Related references
Note: Only part of the references are listed.Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review
Aleksi J. Hendricks et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2021)
A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis
Nurhan Kasap et al.
CLINICAL IMMUNOLOGY (2021)
Dupilumab for severe generalized eczematous eruption complicating common variable immunodeficiency
Nicolas Votquenne et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2021)
Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review
Sean Igelman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Dupilumab as a novel steroid-sparing treatment for IgG4-related disease
Rachel S. Simpson et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome
Romain Levy et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2020)
Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome
Georgios Sogkas et al.
CLINICAL IMMUNOLOGY (2020)
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Insights into immunity from clinical and basic science studies of DOCK8 immunodeficiency syndrome
Helen C. Su et al.
IMMUNOLOGICAL REVIEWS (2019)
Severity strata for five patient-reported outcomes in adults with atopic dermatitis
[Anonymous]
BRITISH JOURNAL OF DERMATOLOGY (2018)
Dedicator of cytokinesis 8-deficient CD4+ T cells are biased to a TH2 effector fate at the expense of TH1 and TH17 cells
Stuart G. Tangye et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
DOCK8 deficiency: Insights into pathophysiology, clinical features and management
Catherine M. Biggs et al.
CLINICAL IMMUNOLOGY (2017)
Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency
Waleed Al-Herz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes TH17 cell differentiation
Sevgi Keles et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Matched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency
Jennifer Cuellar-Rodriguez et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency
Karin R. Engelhardt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients
Susanne E. Aydin et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2015)
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cutaneous Manifestations of DOCK8 Deficiency Syndrome
Emily Y. Chu et al.
ARCHIVES OF DERMATOLOGY (2012)
Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation
S. A. Gatz et al.
BONE MARROW TRANSPLANTATION (2011)
Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency
Douglas R. McDonald et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Successful Long-Term Correction of Autosomal Recessive Hyper-IgE Syndrome due to DOCK8 Deficiency by Hematopoietic Stem Cell Transplantation
T. C. Bittner et al.
KLINISCHE PADIATRIE (2010)
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome
Karin R. Engelhardt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Combined Immunodeficiency Associated with DOCK8 Mutations
Qian Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
